| Adverse drug reactions spontaneously reported at a tertiary care hospital and preventable measures implemented LC Abu Esba, G Al Mardawi, MI AlJasser, B Aljohani, A Abu Alburak Journal of Clinical Pharmacy and Therapeutics 46 (2), 460-469, 2021 | 19 | 2021 |
| Forensic toxicology: drug use and misuse D Holt Royal Society of Chemistry, 2016 | 15 | 2016 |
| Development and validation of a HPLC-UV method for dissolution testing of ciclosporin: its application to the measurement of brand and generic versions from different countries B Aljohani, FF Alotaibi, E Ghazaly, JA Jaber, D Perrett, A Johnston J. Bioequiv. Availab 9, 509-519, 2017 | 9 | 2017 |
| Prospects of Establishing a Saudi Version of the United States Food and Drug Administration Orange Book RA Yazed AlRuthia, Badr Aljohani, Wejdan R. Alsharif, Hala H. Alrasheed ... Health Policy and Technology, 2020 | 4* | 2020 |
| Therapeutics discovery: From bench to first in-human trials EM Al-Hujaily, T Khatlani, Z Alehaideb, R Ali, B Almuzaini, BM Alrfaei, ... Biomedical Reports 8 (3), 275-282, 2018 | 3 | 2018 |
| Observing INR Results in Patients Who Switched from Brand-Name to Generic Warfarin during the COVID-19 Pandemic at KAMC, Riyadh, Saudi Arabia FA AlSehli, B Aljohani, MA Albakr, GS Aljarallah, RM Alajlan, ... Saudi Journal of Clinical Pharmacy 3 (3), 123-129, 2024 | | 2024 |
| Pharmaceutical Bioequivalence Studies: Ensuring Safety, Effectiveness and High Quality BA Aljohani Queen Mary University of London, 2016 | | 2016 |
| Substandard and Counterfeit Medicines B Aljohani | | 2016 |
| Development and validation of a hplc method for ciclosporin: its application to measurement of brand and generic versions from different countries B Aljohani, F Al Otaibi, E Ghazaly, D Perrett, A Johnston BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 73 (6), 1007-1007, 2012 | | 2012 |
